Prevent Organ Rejection with Once-Daily Dosing

Advagraf ER (tacrolimus extended-release) is a trusted immunosuppressant used to prevent organ rejection in kidney and liver transplant patients. By regulating the body’s immune response, it helps ensure a successful transplant outcome while reducing the risk of complications.

Extended-Release Formula for Consistent Protection

Advagraf ER features an advanced extended-release formulation, allowing for once-daily dosing. This provides stable medication levels throughout the day, improving adherence and ensuring continuous immunosuppressive protection.

Trusted by Transplant Specialists Worldwide

Prescribed by healthcare professionals globally, Advagraf ER is a proven treatment for transplant patients. When taken as directed, it supports long-term graft survival, promoting better post-transplant health and recovery.